Cargando…
Evolving treatment landscape of immunotherapy in breast cancer: current issues and future perspectives
Immune checkpoint inhibitors (ICIs) deeply changed the treatment landscape of breast cancer (BC). In particular, anti-programmed-death (ligand) 1 antibodies were approved for the treatment of triple-negative breast cancer (TNBC), both in first line for metastatic disease and in neoadjuvant setting,...
Autores principales: | Valenza, Carmine, Rizzo, Graziella, Passalacqua, Maria Ilenia, Boldrini, Laura, Corti, Chiara, Trapani, Dario, Curigliano, Giuseppe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9893403/ https://www.ncbi.nlm.nih.gov/pubmed/36743524 http://dx.doi.org/10.1177/17588359221146129 |
Ejemplares similares
-
Tumor Infiltrating Lymphocytes across Breast Cancer Subtypes: Current Issues for Biomarker Assessment
por: Valenza, Carmine, et al.
Publicado: (2023) -
Resistance to Antibody-Drug Conjugates Targeting HER2 in Breast Cancer: Molecular Landscape and Future Challenges
por: Guidi, Lorenzo, et al.
Publicado: (2023) -
Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy
por: Viale, Giulia, et al.
Publicado: (2017) -
The evolving landscape of immunotherapy for the treatment of allergic conditions
por: Pandya, Aarti, et al.
Publicado: (2023) -
Immunotherapies for pediatric cancer: current landscape and future perspectives
por: Hutzen, Brian, et al.
Publicado: (2019)